https://scholars.lib.ntu.edu.tw/handle/123456789/627792
標題: | The landscape of novel and complementary targets for immunotherapy: an analysis of gene expression in the tumor microenvironment | 作者: | Gaffney, Stephen G Perry, Elizabeth B PING-MIN CHEN Greenstein, Andrew Kaech, Susan M Townsend, Jeffrey P |
關鍵字: | RNA-seq; T lymphocyte; cancer genomics; immunotherapy; tumor microenvironment | 公開日期: | 16-七月-2019 | 卷: | 10 | 期: | 44 | 來源出版物: | Oncotarget | 摘要: | Background: Immunotherapies targeting immune checkpoint proteins CTLA-4, PD-1, and PD-L1 have saved lives, but these therapies have only been effective in some patients. Patients positive for expression of immune checkpoint proteins in the tumor microenvironment show better response to immune checkpoint inhibitors. Consequently, knowledge of which genes are consistently expressed in lymphocytes within the tumor microenvironment can convey potentially effective and complementary new immunotherapy targets. Results: We identified 54 genes that have higher co-expression with the pan T-cell marker CD3E than CTLA4 or PDCD1. In a dataset of 26 patients who received anti-PD-1 therapy, we observed that co-expression between CD3E and PDCD1 was higher among responders than non-responders, supporting our correlation-based approach. Conclusions: The genes highlighted in these analyses, which include CD6, TIGIT, CD96, and SLAMF6, warrant further investigation of their therapeutic potential. Methods: We analyzed and ranked genes that were co-expressed with the pan T-cell marker CD3E in 9,601 human tumors, spanning 31 cancer types. To further identify targets that may be complementary to existing PD-1 therapy, we examined and ranked genes with high CD3E co-expression and relatively low PDCD1 co-expression. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/627792 | ISSN: | 1949-2553 | DOI: | 10.18632/oncotarget.27027 |
顯示於: | 生物化學暨分子生物學科研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。